TIGENIX NV
7Patents
5Active
7Granted
40Portfolio score
Filing activity: Apr 24, 2003 → Mar 17, 2014 · 3 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7485310B2 | Use of CXCL6 chemokine in the prevention or repair of cartilage defects | Human Necessities | 15 | Expired |
| US10660920B2 | Lymphocyte biomarkers for determining the clinical response to cell therapy | Physics | 1 | Active |
| US7482114B2 | In vivo assay and molecular markers for testing the phenotypic stability of cell populations, and selected cell populations for autologous transplantation | Human Necessities | 1 | Expired |
| US9089598B2 | Method of treating connective tissue defect using chondrocytes selected for phenotypic stability | Emerging Cross-Sectional Technologies | 0 | Active |
| US9402709B2 | Collagen gel for bonding porous collagen-based materials with non-porous collagen-based materials | Chemistry; Metallurgy | 0 | Active |
| US7842502B2 | Use of CXCL6 chemokine for inducing precursor cells into chondrocytes | Human Necessities | 0 | Active |
| US7863045B2 | Isolation of skeletal precursor cells | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.